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Mice infected with Schistosoma mansoni were treated with oxamniquine, praziquantel, artesunate at the pre-pat-
ent phase, aiming at observing schistogram alterations. Half of the animals were perfused five days post-treatment 
for counting and classification of immature worms, based on pre-established morphological criteria (schistogram); 
the remaining animals were evaluated 42 or 100 days after infection and perfusion of the portal-system was per-
formed for collection and counting of adult worms and oogram. It was observed that oxamniquine and artesunate 
treatment administered at the pre-postural phase causes significant reduction in the number of immature and adult 
worms. However, there was little reduction with praziquantel when used at the dose of 400 mg/kg for treatments ad-
ministered 14, 15, 21 or 23 days post-infection. Artesunate was responsible for significant alterations in development 
of young worms, as well as for a higher number of worms presenting intestinal damages. Immature adult worms were 
detected in mice treated with artesunate or oxamniquine at the pre-patent phase of infection and recovered by perfu-
sion 100 days after infection. Schistogram proved to be a very useful tool for experimental evaluation of the activity 
of antischistosomal drugs and a good model to identify the most sensitive stages to drugs.
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 One of the major challenges of schistosomiasis che-
motherapy is the efficacy of treatment at the initial phase 
of the disease. It is well known that Schistosoma man-
soni development from the schistosomulum stage to the 
adult worm is accomplished through evolutive stages, 
with morphological changes and a large body growth. 
Faust et al. (1934) using experimental infection in rats, 
rabbits and monkeys observed that this development oc-
curs in an asynchronous way.
Several authors have already demonstrated that at the 
initial stage of development (immature worms) S. mansoni 
is less susceptible to chemotherapeutic action, including 
oxamniquine and praziquantel (Xiao et al. 1985, Sabah et 
al. 1986, Silva et al. 2003, Pica-Mattoccia & Cioli 2004, 
Botros et al. 2005, Grandière-Pérez et al. 2006).
Sabah et al. (1986) demonstrated that S. mansoni im-
mature worm is less susceptible at least to six antischis-
tosomal drugs: antimonium and potassium artesunate, 
hycanthone, oxamniquine, niridazol, amoscanato and 
praziquantel, used at doses considered curative against 
adult worms. The six tested drugs were ineffective 
against worms already housed in the portal system. It is 
noteworthy that hycanthone, oxamniquine, praziquantel 
and niridazol showed activity against schistosomula up 
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to two-week-old. It was observed that there was a greater 
activity against mature adult worms than in five-six-
week-old worms. An important result was the total or 
partial activity on two-five-week-old worms.
Treatment of infection at the initial stages would 
bring a great advantage for vertebrate hosts, since it 
would avoid production of eggs and, consequently, for-
mation of granulomas, which are the fundamental ele-
ments of the pathology of the disease (Bogliolo 1959, 
Warren 1968, Enk et al. 2008, Coelho et al. 2009).
The fundamentals of the present study are based on 
the well established biological fact that immature worms, 
by reasons related to time required to reach the portal-
hepatic system, coming from the lungs, present a marked 
evolutive asynchronism (Faust et al. 1934, Barbosa et al. 
1978). This fact could explain, at least in part, the dif-
ficulty of conventional antischistosomal drugs, admin-
istered at the initial phase of infection, to eliminate with 
efficacy all the parasites, considering the difference of 
susceptibility to the drug regarding the mentioned stage 
of worm development.
The procedure related to counting of schistosomula 
recovered by perfusion of animals previously infected 
with S. mansoni cercariae and their classification based 
on morphological criteria (1st-6th stages), according to 
intestinal development generating the percentage related 
to each evolutive stage in the portal system, is called 
schistogram (Barbosa et al. 1978).
This study evaluated the activity of oxamniquine, 
praziquantel and artesunate, administered alone or in as-
sociation, in the initial phases of infection using schisto-
gram as a parameter, trying to identify the developmental 
stages that are most vulnerable or resistant to drug action. 
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For treatment three antischistosomal drugs, which 
are currently used for schistosomiasis treatment, were 
selected oxamniquine, praziquantel and artesunate, ad-
ministered alone or in association (Utzinger et al. 2002, 
Lu et al. 2004, Shaohong et al. 2006).
MATERIALS AND METHODS
Infection of mice - Swiss female mice, weighing ap-
proximately 20 g, infected with 200 ± 10 S. mansoni cer-
cariae (LE strain), by subcutaneous route, or 50 cercar-
iae when mice were sacrificed 100 days after infection, 
were used in this study.
Treatment of animals - Oxamniquine, praziquantel and 
artesunate were administered in monotherapy or in asso-
ciation (praziquantel and artesunate), always with single 
dose and by oral route. The schedules utilised for treat-
ments were as follows: oxamniquine - 200 mg/kg or 400 
mg/kg weight in monotherapy, praziquantel - 400 mg/kg 
or 800 mg/kg in monotherapy or in association with 300 
mg/kg or 600 mg/kg artesunate, which was also used in 
monotherapy with the same doses as the association.
The animals were treated 14, 15, 21 or 23 days post-
infection and the perfusion of mice was performed five, 
42 or 100 days after treatment for collection, counting 
and classification of worms.
Evaluation of schistosomicidal activity - In order to 
evaluate the activity of drugs at the pre-patent (pre-pos-
tural) phase of infection, the animals were submitted to 
euthanasia by cervical fracture (experimental groups and 
controls in all the schedules). After that, the animals were 
submitted to perfusion of the mesenteric veins and liver, 
according to the technique prescribed by Pellegrino and 
Siqueira (1956) for worm recovery. After perfusion of 
the portal system, the recovered immature worms were 
counted and classified using a stereomicroscope. Morpho-
logical criteria, based on the development of the digestive 
tract of the parasite after ingestion of blood, were used for 
its classification regarding its evolutive stage, constituting 
the schistogram (Barbosa et al. 1978).
For activity evaluation at the patent phase, perfu-
sion of mesenteric veins and liver was performed aim-
ing at recovering and counting adult worms (Pellegrino 
& Siqueira 1956). The livers were crushed between slide 
and coverslip and observed under a stereomicroscope for 
counting of dead worms; fragments from the distal por-
tion of the small intestine, measuring approximately 1 cm, 
were compressed between two plastic slides and observed 
under optical microscope for detection of S. mansoni eggs 
at different evolutive stages (Pellegrino et al. 1962).
Groups of untreated infected mice (control of infec-
tion) were kept in all the schedules and were submitted to 
the same procedure for treated animals, except treatment.
Schistogram changes were observed taking into ac-
count differences in the average of recovered imma-
ture worms, at each evolutive stage after comparison 
to untreated control and percentage in reduction of re-
covered adult worms of treated groups in relation to 
untreated control.
The average of recovered worms, distribution of worms 
in the liver and mesentery, percentage of dead worms in 
the liver and of oogram changes were indicators of drug 
activity on the adult worm (Pellegrino & Katz 1968).
Statistical analyses - All the results were submit-
ted to normality test. Kruskal-Wallis test, followed by 
Dunn’s multiple comparison, were applied to non-para-
metric data, whereas Pearson’s X2 test and ANOVA, fol-
lowed by Tukey’s multiple comparisons, were applied to 
parametric data.
Ethics - The guidelines of the Ethical Committee for 
the use of experimental animals of Oswaldo Cruz Foun-
dation were followed (CEUA L-018/09).
RESULTS
The results obtained in all the experiments are pre-
sented in Tables I-IV.
Except for praziquantel, administered at the dose of 
400 mg/kg, 15 or 23 days post-infection, it was observed 
a significant decrease in the mean number of worms re-
covered by perfusion in all the other therapeutic sched-
ules used. Oxamniquine reduced from 70.2-57% the 
young worms at fourth evolutive stage, when treatment 
was administered 15 days after infection and it was ob-
served a statistically significant increase in the percent-
age of worms (4th evolutive stage) when the drug was 
used 23 days after infection; the drug also reduced 70% 
of the worms at the sixth evolutive stage and increased 
from 1% (control group) to 13.3% (oxamniquine 400 mg/
kg) the percentage of unidentified worms due to intestinal 
damages (NI), when treatment was administered 23 days 
post-infection. Treatment with artesunate was respon-
sible for a significant decrease in the percentage of young 
worms at third stage (300 mg/kg, treatment on 15 days 
after infection), as well as an increase in the percentage 
of worms at second stage; there was also a decrease about 
30% and 50% in the percentage of worms at third and 
fourth stages, respectively (dose of 600 mg/kg, treatment 
15 days after infection) and diminished by almost half the 
percentage of worms at fourth, fifth and sixth evolutive 
stages (dose of 600 mg/kg, treatment 23 days after infec-
tion). The percentage of immature worms, which could 
not be assigned to any of the six stages and were con-
sidered as NI, was at most 4% in untreated mice. On the 
other hand, a significant increase in the percentage of NI 
could be observed, varying from 16.9% (animals treated 
15 days post-infection with 300 mg/kg artesunate) to 
38.8%, when artesunate (600 mg/kg) was administered 
23 days after infection. In relation to the other two drugs, 
only oxamniquine (400 mg/kg, treatment 23 days after 
infection) showed a significant increase in the percentage 
of NI (13%, p ≤ 0.05) (Table I).
In all the schedules using different doses of oxam-
niquine, artesunate and praziquantel, 15 or 23 days post-
infection, activity evaluation performed 42 days after 
infection showed a significant reduction in the mean of 
recovered worms, varying from 25.7% (when 200 mg/
kg oxamniquine or 400 mg/kg praziquantel were used) 
to 75% when treatment with 400 mg/kg oxaminiquine 
was administered 23 days after infection. The animals 
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TABLE I
Distribution of young worms recovered from mice infected with 200 Schistosoma mansoni cercariae treated with single dose 
by oral route as monotherapy and submitted to euthanasia (treated and control groups) five days after treatment
Animals
(n)
Distribution of schistosomules per evolutive stage 
(%)





Mean of worm  
(% reduction) 1 2 3 4 5 6 NI
Oxamniquine 200 15 13 13 12.5 (57)a 0.5 12.2 36.8 50 0 0 0.5
Artesunate 300 15 13 13 10.0 (65.6)a 3.8 8.5 10.8b 57.7 2.3 0 16.9b
Praziquantel 400 15 13 13 16.5 (43.3)a 0.9 6 24.2 67.5 0.9 0 0.5
Control - - 12 29.1 (0) 3.1 7.2 26.4 59 0.3 0 4
Oxamniquine 200 23 13 12 37.0 (31.2) 0 0 0.7 14.6 37.8 46.8 0
Artesunate 300 23 13 13 27.8 (48.3)a 0 0.3 0.3 13 31.6 54.8 0
Praziquantel 400 23 13 13 42.7 (20.6) 0 0 2 13.5 38.3 46.2 0
Control - - 11 53.8 (0) 0 0.3 1.2 8.9 32.9 56.7 0
Oxamniquine 400 15 13 9 33.3 (43.7)a 1.7 17 24.3 57a 0 0 6
Artesunate 600 15 13 12 24.1 (59.2)a 6.2 19a 12.1a 35.6a 0 0 27b
Praziquantel 800 15 13 9 28.9 (51.1)a 1.5 13.8 29.6 54.6a 0 0 0.4
Control - - 11 49.4 (16.4) 0.9 7.4 18.8 70.2 0.6 0 2.2
Oxamniquine 400 23 13 12 28.9 (51.1)a 0 0.3 4 27.7a 41.8 13a 13.3a
Artesunate 600 23 13 12 25.8 (56.3)a 0 0.3 0.3 4.9a 32c 23.6a 38.8b
Praziquantel 800 23 13 13 40.5 (31.6)a 0 0.6 1.4 10.5 61.2 25.8a 0.4
Control - - 12 59.1 (0) 0 0.1 1.3 10.4 42 45.1 1
a: statistically signiﬁcant difference in relation to control (p ≤ 0.05); b: statistically signiﬁcant difference of artesunate in rela-
tion to praziquantel and oxamniquine (p ≤ 0.05); c: statistically signiﬁcant difference of artesunate in relation to praziquantel 
(p ≤ 0.05); NI: schistosomules with damaged intestines that did not allow their identification.
treated with 200 mg/kg or 400 mg/kg oxamniquine, or 
with 300 mg/kg or 600 mg/kg artesunate, 15 or 23 days 
after infection, showed a significant statistical reduc-
tion in the number of collected male and female worms. 
Treatment with praziquantel resulted in significant re-
duction only in the number of male worms, about 40% in 
reduction when doses of 400 mg/kg or 800 mg/kg were 
administered 23 or 15 days post-infection, respectively.
The percentage of immature worms collected reached 
a maximum of 2.4% in untreated mice of the control group. 
Treatment with 300 mg/kg artesunate, 15 days after infec-
tion or 600 mg/kg 23 days after infection, significantly 
increased the percentage of immature worms (15.4% and 
40.4%, respectively). Treatment with 200 mg/kg or 400 
mg/kg oxamniquine, 23 days post-infection, significantly 
increased the percentage of recovered immature worms 
(20.3% and 34.9%, respectively). When treatment with 
400 mg/kg oxamniquine was administered 15 days after 
infection, there was a significant statistical increase of 
16.8% in the percentage of immature worms (Table II).
In the experiments using praziquantel and artesunate 
in monotherapy or in association, it was observed a sig-
nificant reduction in the mean number of worms collect-
ed by perfusion, except for the groups treated with 400 
mg/kg praziquantel, 14 or 21 days after infection. When 
treatments performed in monotherapy were compared 
with those ones using drugs in association, the results re-
lated to decrease in the average of worms were similar. 
Praziquantel used in monotherapy significantly reduced 
the percentage of fourth stage worms (400 mg/kg and 800 
mg/kg administered 21 days after infection); artesunate 
in monotherapy was more effective reducing the number 
of worms (3rd and 4th stages), when used at the doses of 
300 mg/kg or 600 mg/kg, 21 days after infection. It was 
observed a significant increase in the number of young 
worms, which were not identified due to intestinal dam-
ages in animals treated with artesunate in monotherapy 
or with other drug in association, but not in treatment 
schedules with only praziquantel (Table III). 
Mice treated with oxamniquine (200 mg/kg or 400 
mg/kg), artesunate (300 mg/kg or 600 mg/kg) or prazi-
quantel (400 mg/kg or 800 mg/kg), 14 or 21 days post-in-
fection, and evaluated 100 days after infection, presented 
a significant reduction in the number of worms (37-74%) 
in relation to the control group. No significant differ-
ence in reduction of the average of worms between the 
treated groups at different schedules could be observed. 
Worm distribution in mesentery and liver was similar to 
the control group and no dead worms were detected in 
the liver. Nevertheless, the oogram was altered in all the 
groups, except in those treated with praziquantel on days 
14 post-infection (Table IV). 
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TABLE II
Adult worm burden recovered from mice infected with 200 Schistosoma mansoni cercariae treated with single dose  










Mean of worm 
(% reduction) Males Females
Immature
worms
Oxamniquine 200 15 13 12 33.7 (46.8)a 194 (49.7)a 191 (53.8)a 19 (4.7)
Artesunate 300 15 13 13 22.5 (61.4)a 129 (66.5)a 134 (66.5)a 45 (15.4)a
Praziquantel 400 15 13 12 41.2 (34.9)a 244 (36.8)a 223 (37.2) 39 (7.7)
Control - - 13 58.4 (0) 386 (0) 355 (0) 18 (0)
Oxamniquine 200 23 12 12 52.4 (25.7) 228 (39.6)a 273 (39.3)a 128 (20.3)a
Artesunate 300 23 12 11 43.7 (43.2)a 200 ( 47.5)a 248 (44.9)a 33 (6.9)
Praziquantel 400 23 12 12 52.4 (25.7) 277 (27.3) 282 (37.8)a 70 (11.1)
Control - - 12 70.6 (0) 381 (0) 450 (0) 18 (0)
Oxamniquine 400 15 15 15 40.8 (55.1)a 233 (65.8)a 270 (60.4)a 104 (16.8)
Artesunate 600 15 13 15 35.1 (61.4)a 241 (63.6)a 261 (61.7)a 24 (4.6)
Praziquantel 800 15 15 15 53.8 (40.9)a 339 (48.8)a 362 (46.9)a 52 (6.9)
Control - - 14 97.5 (0) 662 (0) 682 (0) 21 (0)
Oxamniquine 400 23 14 13 20.9 (75)a 64 (88.9)a 113 (77.3)a 95 (34.9)a
Artesunate 600 23 14 14 327 (57.9)a 141 (76.6)a 132 (73.4)a 185 (40.4)a
Praziquantel 800 23 14 12 56.8 (37.4)a 329 (42.9)a 314 (36.8) 38 (5.6)
Control - - 13 83.8 (0) 577 (0) 497 (0) 15 (0)
a: statistically signiﬁcant difference in relation to control (p ≤ 0.05).
TABLE III
Distribution of young worms recovered from mice infected with 200 Schistosoma mansoni cercariae treated 
with single dose by oral route as monotherapy and combination of drugs and submitted to euthanasia  
(treated and control groups) five days after treatment
Animals
(n)
Distribution of schistosomules  







Mean of worm 
(% reduction) 1 2 3 4 5 6 NI
Praziquantel 400 14 11 10 29.3 (32.6) 0.3 5 24 68 0.3 0 1.6
Praziquantel 800 14 11 11 23.5 (46)a 0.4 4.7 31 54.3a 6.6 0 3.1
Artesunate 300 14 11 10 17.9 (58.9)a 1.2 8.7 16.9 a 53.5a 0.6 0 19.2a
Artesunate 600 14 11 9 7.7 (82.3)a 1.4 20.3a 7.2 a 34.8a 1.4 0 34.8a
Praziquantel 400 + artesunate 300 14 12 12 9.8 (77.5)a 2.5 16.9 29.7 a 42.4a 0 0 8.5a
Praziquantel 800 + artesunate 600 14 12 11 9.1(79.1)a 1 5.9 18.8 55.4a 1 0 17.8a
Control - - 12 43.5 (0) 0.6 3.8 18.6 73.9 2.3 0 0.8
Praziquantel 400 21 11 10 57.6 (5.6) 0 1.7 3.8 34.9 44.4 13.7a 1.4
Praziquantel 800 21 11 11 36.0 (41)a 0 0.3 9.6 34.1 45.4 9.6a 0.8
Artesunate 300 21 11 11 26.9 (55.9)a 0 0.3 1.4 10.1 29.4 14.5a 44.3a
Artesunate 600 21 12 12 20.6 (66.2)a 0 0.8 0 15.4 35.2 4.9a 43.7a
Praziquantel 400 + artesunate 300 21 12 11 29.3 (52)a 0 0.9 3.4 27 27.6 4.7a 36.6a
Praziquantel 800 + artesunate 600 21 12 11 19.2 (68.5)a 0 0.5 4.3 19.9 38.9 8.1a 28.4a
Control - - 11 61 (0) 0 0.3 3.3 21.6 37.9 35.2 1.8
a: statistically signiﬁcant difference in relation to control (p ≤ 0.05); NI: schistosomules with damaged intestines that did not 
allow their identification.
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TABLE IV
Results obtained using mice experimentally infected with 50 Schistosoma mansoni cercariae treated  


















Oxamniquine 200 14 15 11 7.1 (65)a 86.2 13.8 0 45.5a
Artesunate 300 14 15 9 7.0 (65.3)a 94.9 5.1 0 11.1
Praziquantel 400 14 15 13 12.6 (37.6) 97.6 2.4 0 0
Oxamniquine 200 21 15 11 7.4 (63.6)a 93.6 6.4 0 27.3
Artesunate 300 21 15 13 5.2 (74.3)a 95.6 4.4 0 16.4
Praziquantel 400 21 15 7 9.3 (54)a 82.4 17.6 0 28.6
Control - - 13 20.2 (0) 88.5 11.5 0 0
Oxamniquine 400 14 15 11 5.2 (67.9)a 76.2 23.8 9.5 63.6a
Artesunate 600 14 15 13 4.5 (72.2)a 81 19 0 15.4
Praziquantel 800 14 15 8 9.5 (41.4) 76.9 23.1 0 0
oxamniquine 400 21 15 12 6.8 (58)a 85.2 14.8 0 58.6a
Artesunate 600 21 15 11 5.7 (64.8)a 87.3 12.7 0 27.3
Praziquantel 800 21 15 7 7.9 (51.2)a 83.6 16.4 0 14.3
Control - - 15 16.2 (0) 86.1 13.9 0 0
a: statistically significant difference in relation to untreated control (p ≤ 0.05).
It is important to emphasise that even performing 
perfusion 100 days after infection, a part of the recov-
ered worms in treated groups (400 mg/kg oxamniquine 
and 600 mg/kg artesunate) remained small and with 
fragile aspect. Most of the females were with a clear-
looking intestine, seeming to be female immature 
worms. In the group treated with artesunate (600 mg/
kg, 21 days post-infection) 16 out of 34 (47.1%) females 
presented immature characteristics, whereas 14 out of 
36 (38.9%) females seemed to be immature in the group 
treated 14 days after infection. In the group treated with 
oxamniquine (400 mg/kg, 21 days post-infection) 22 out 
of 49 (44.9%) females showed an immature aspect, while 
eight out of 28 (28.6%) females showed an immature as-
pect in the group treated 14 days after infection.
DISCUSSION
The asynchronous development of S. mansoni at the 
pre-patent phase was clearly observed in this study and 
the distribution of the immature worms recovered in the 
untreated control groups was similar to that reported by 
Barbosa et al. (1978). 
These results here presented show that the drug in-
terferes in the worm development, slowing or blocking 
the development of parasites, since significant percent-
ages of worms with an immature aspect were detected 
up to 100 days after infection. This original finding has 
important implications in the fields of pathology, diag-
nosis and epidemiology of schistosomiasis.
Oogram alteration was observed in worms of the 
group treated with oxamniquine (200 mg/kg or 400 mg/
kg), 14 or 21 days after infection, and submitted to eu-
thanasia 42 days post-infection, indicating that treatment 
interfered with sexual maturation of the worms, since 
immature females were recovered.
In the animals treated with 300 mg/kg or 600 mg/
kg artesunate, 14 or 21 days post-infection, a small per-
centage of oogram changes could be observed, although 
not statistically significant, is of relevance. According 
to Araújo et al. (1999), treatment with artesunate, at the 
postural phase, is capable of interrupting egg-laying 
only temporarily.
Praziquantel and derivatives of artesunate shown to 
be effective in different stages of worm development, be-
ing suggested that these drugs would be more efficacious 
when administered in association than in monotherapy 
(Inyang-Etoh et al. 2008, Abdul-Ghani et al. 2009). Prom-
ising results were obtained with praziquantel/artesunate in 
association, when administered in S. mansoni and Schisto-
soma japonicum infected mice, presenting immature and 
mature worms, simultaneously (Utzinger et al. 2001).
These data were not corroborated by De Clercq et al. 
(2000) in infected patients, in an endemic area for S. man-
soni. In the present study, the results obtained with combi-
nation of 400 mg/kg praziquantel + 300 mg/kg artesunate, 
or 800 mg/kg praziquantel + 600 mg/kg artesunate, ad-
ministered 14 or 21 days post-infection, did not show ther-
apeutic advantages, since the profile presented by drug 
associations was similar to that observed when artesunate 
was administered alone. Perhaps, a better result can be ob-
tained if the association is used in mixed infections, with 
adult and immature worms (Utzinger et al. 2001).
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The experimental chemotherapy at the pre-postural 
phase of S. mansoni is a field of great importance for de-
velopment of antischistosomal drugs, due to its potential 
to eliminate the parasitism before lying of eggs, which 
cause the major injuries responsible for the disease - the 
granulomatous inflammatory reactions (Enk et al. 2008, 
Coelho et al. 2009). Thus, experimental chemotherapy is 
of the utmost importance and deserves a greater number 
of studies in this direction.
Worms treated at the early phase of infection (un-
fertile worms), 100 days post-chemotherapy, could 
maintain an immunological response, as well as the 
presence of circulating antigens in blood, even in ab-
sence of eggs in the faeces.
These findings represent a major cause of confusion 
regarding the interpretation of schistosomiasis mansoni 
diagnosis: the absence of eggs in the faeces, but mainte-
nance of specific immune response, the presence of circu-
lating antigens and genetic material of S. mansoni worms 
(detected by polymerase chain reaction techniques).
The results obtained allow us to conclude that the 
schistogram method used in this study proved to be a 
useful tool for experimental evaluation of the activity 
of antischistosomal drugs, at the early stages of infec-
tion, besides being a good model to investigate which 
of the evolutive stages are more sensitive to antischis-
tosomal drugs. 
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